Exosome In Vitro Functional Models

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide comprehensive in vitro functional model services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), membrane vesicles (MVs) from Gram-positive bacteria, fungal EVs, and phage-associated vesicles. Our platform integrates macrophage immunomodulation assays, anti-inflammatory screening, intestinal epithelial barrier repair models, cellular uptake and trafficking analysis, and mechanism-of-action pathway studies into a single, standardized workflow that validates the biological activity of mEV preparations and supports therapeutic, vaccine, probiotic, and cosmetic product development.

Unlike generic cell assay CROs that apply mammalian exosome protocols to microbial samples without adaptation, we have optimized every cell model, co-culture parameter, and readout criterion for the unique surface properties, cargo composition, and host-interaction mechanisms of microbial vesicles. From purified vesicle suspension to publication-ready functional report, clients receive validated bioactivity endpoints, dose-response curves, and mechanistic pathway data that support product efficacy claims, CMC documentation, and regulatory submissions. Contact us to discuss your specific in vitro functional validation requirements.

Scientific schematic of integrated in vitro functional model platform for microbial extracellular vesicles, showing macrophage immunomodulation, anti-inflammatory screening, barrier repair models, cellular uptake analysis, and mechanism-of-action pathway study modules.
Figure 1. Schematic overview of the integrated in vitro functional model platform for microbial extracellular vesicles, spanning macrophage immunomodulation assays, anti-inflammatory screening, intestinal epithelial barrier repair models, cellular uptake and trafficking analysis, and mechanism-of-action pathway studies.

Services

Service Workflow

Commercial end-to-end service workflow diagram for in vitro functional models showing seven stages from sample inquiry through cell model selection, vesicle dosing, functional assay execution, mechanistic profiling, data analysis, pathway mapping, and final report delivery.

Inquiry

Service Details

Biological cross-section illustration showing THP-1 derived macrophages polarizing from M1 pro-inflammatory phenotype to M2 anti-inflammatory phenotype upon microbial vesicle treatment, with surface marker expression and cytokine secretion visualized.

Macrophage Immunomodulation & Polarization Assays

We evaluate the immunomodulatory potency of mEVs using human monocytic leukemia THP-1 cells differentiated into macrophage-like cells and primary murine bone marrow-derived macrophages (BMDMs). M1/M2 surface markers (CD80, CD86, CD206, CD163, CD209) are quantified by flow cytometry, and cytokine profiling measures IL-10, IL-12, TGF-β, TNF-α, and IL-6 in culture supernatants using multiplex bead arrays. M1 suppression studies assess pro-inflammatory marker expression in LPS/IFN-γ-activated macrophages co-cultured with mEVs. This service delivers polarization index data, cytokine concentration tables, and dose-response curves to validate immunomodulatory claims for probiotic-derived vesicle and anti-inflammatory therapeutic products.

Molecular close-up illustration showing LPS-stimulated RAW 264.7 macrophage with internalized microbial vesicles, suppressed NF-kB signaling, reduced TNF-alpha secretion, and elevated IL-10 production visualized as molecular signaling cascades.

Anti-Inflammatory Screening & Cytokine Profiling

We assess the anti-inflammatory bioactivity of mEVs using LPS-stimulated RAW 264.7 murine macrophages, THP-1-derived macrophages, and primary human peripheral blood mononuclear cells (PBMCs). Pro-inflammatory cytokine suppression (TNF-α, IL-1β, IL-6, IL-12) and anti-inflammatory cytokine induction (IL-10, TGF-β) are quantified by ELISA or multiplex cytokine arrays. NF-κB and MAPK reporter assays provide pathway-level mechanistic insight. Deliverables include IC₅₀ values, cytokine suppression curves, and NF-κB inhibition dose-response data to support anti-inflammatory efficacy claims and mechanism-of-action documentation.

Macroscopic biological scene showing a Caco-2 intestinal epithelial monolayer with tight junction proteins ZO-1 and occludin forming a sealed barrier, with microbial vesicles approaching from the apical side and macrophages in the basolateral compartment.

Intestinal Epithelial Barrier Repair Models

We evaluate mEV-mediated barrier repair using Caco-2 and HT-29 intestinal epithelial cell monolayers cultured on Transwell inserts. Barrier integrity is measured by transepithelial electrical resistance (TEER) and FITC-dextran paracellular permeability. Tight junction protein expression (ZO-1, occludin, claudin-1, claudin-4) is assessed by immunofluorescence confocal microscopy and Western blot. Inflammation-induced barrier disruption models challenge monolayers with TNF-α/IFN-γ or LPS before mEV treatment to evaluate recovery kinetics. Co-culture systems with macrophages in the basolateral chamber enable assessment of immune-epithelial crosstalk. This service delivers TEER recovery curves, permeability data, tight junction immunofluorescence images, and Western blot panels for gut-targeted probiotic vesicle and therapeutic mEV validation.

Process flow illustration showing fluorescent-labeled microbial vesicles approaching the cell membrane, undergoing endocytosis, trafficking through early endosomes and lysosomes, with intracellular cargo release visualized in a step-by-step sequence.

Cellular Uptake & Intracellular Trafficking Analysis

We quantify and visualize mEV internalization by recipient cells using fluorescent labeling combined with flow cytometry and confocal microscopy. Time-course uptake kinetics determine saturation binding and internalization rates. Co-localization studies with endosomal and lysosomal markers elucidate intracellular trafficking routes. For cargo tracking, mEVs are loaded with fluorescent reporters, and cytosolic release is monitored by live-cell imaging. Deliverables include uptake kinetic plots, percentage positive cells, mean fluorescence intensity data, and confocal images to validate delivery efficiency and support formulation optimization for mEV-based drug delivery systems.

Abstract data visualization showing a signaling pathway network map with NF-kB, MAPK-ERK, PI3K-Akt, and NLRP3 inflammasome nodes, with microbial vesicle intervention points highlighted and downstream gene expression heatmaps displayed.

Mechanism-of-Action Pathway Analysis

We dissect the molecular mechanisms underlying mEV bioactivity using reporter gene assays, Western blot pathway profiling, and quantitative PCR. Pathway panels cover NF-κB, MAPK (ERK, p38, JNK), PI3K-Akt, STAT, and NLRP3 inflammasome signaling. Reporter assays use TLR and NF-κB reporter cell lines with secreted alkaline phosphatase readout. Western blot panels quantify phosphorylated and total protein levels for key signaling nodes. Targeted qPCR panels measure mRNA expression of inflammation, barrier function, and immune regulation genes. Results include pathway activation/inhibition heatmaps, dose-dependent signaling response curves, and integrated mechanism-of-action hypotheses to support intellectual property claims and regulatory mechanism-of-action documentation.

Service Specifications & QC Standards

Instrumentation & Capability

Flow Cytometry: Multi-parameter analytical systems for macrophage polarization panel analysis.
Cytokine Profiling: Multiplex bead-based cytokine arrays and automated ELISA platforms.
Confocal Microscopy: Laser scanning systems with live-cell imaging and co-localization capabilities.
TEER Measurement: Epithelial voltohmmeter systems for barrier integrity assessment.
Reporter Assays: TLR and NF-κB reporter cell lines with colorimetric detection.
Western Blot: Chemiluminescence-based detection with phosphorylation-specific and total protein antibodies.
qPCR: Real-time quantitative PCR with probe-based detection and relative quantification analysis.
Cell Models: THP-1, RAW 264.7, Caco-2, HT-29, HEK293, primary human PBMCs, primary murine BMDMs.

Typical Data Range

M2 polarization marker induction: 1.5–8-fold increase vs. vehicle control (strain dependent).
M1 suppression: 20–80% reduction in TNF-α and IL-6 (concentration dependent).
Anti-inflammatory IC₅₀: 10⁷–10¹⁰ particles/mL (strain dependent).
Barrier repair TEER recovery: 20–60% restoration after inflammatory insult.
Tight junction protein upregulation: 1.5–5-fold increase in ZO-1 and occludin expression.
Cellular uptake efficiency: 10–80% positive cells at 24 h (cell type and vesicle dependent).
Pathway inhibition: 30–90% reduction in NF-κB or ERK phosphorylation.

Turnaround Time

Project Type	Timeline
Macrophage polarization assay	7–10 business days
Anti-inflammatory cytokine profiling	5–7 business days
Barrier repair TEER/permeability study	10–14 business days
Cellular uptake kinetics	5–7 business days
Intracellular trafficking analysis	7–10 business days
Mechanism-of-action pathway panel	7–10 business days
Standard functional package (all assays)	21–28 business days
Expedited analysis	+50% fee, 50% time reduction

Timeline may vary based on cell model availability, vesicle type, and assay complexity.

Deliverables

Macrophage polarization: Flow cytometry histograms, M1/M2 marker expression tables, cytokine concentration data.
Anti-inflammatory screening: IC₅₀ values, cytokine suppression curves, NF-κB inhibition data.
Barrier repair: TEER recovery curves, permeability data, tight junction immunofluorescence images, Western blot panels.
Cellular uptake: Uptake kinetic plots, percentage positive cells, mean fluorescence intensity data, confocal images.
Mechanism-of-action: Pathway activation/inhibition heatmaps, Western blot quantification, qPCR expression data.
Integrated functional report: Cross-assay correlation analysis, statistical summary, mechanism hypothesis.

Quality Control

Positive controls: Dexamethasone (anti-inflammatory), LPS (pro-inflammatory stimulus), TNF-α/IFN-γ (barrier disruption).
Negative controls: Vehicle-only (PBS), heat-inactivated vesicles, vesicle-depleted supernatant.
Cell viability validation: ≥ 95% viability for untreated controls at assay start and endpoint.
Intra-assay CV ≤ 15%; inter-assay CV ≤ 20% for all quantitative endpoints.
Dose-response curve quality: R² ≥ 0.90 for IC₅₀ determination.
LPS contamination check: LAL assay on all vesicle preparations to exclude endotoxin-driven artifacts.
Compliance checklist for minimal characterization requirements aligned with industry guidelines for extracellular vesicle studies.
Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.

Sample Requirements

Required Information	Optional Information	Not Accepted
Sample type (OMVs, MVs, fungal EVs, phage-associated vesicles) Purified vesicle suspension Approximate particle concentration (NTA data preferred) Sample volume (minimum 200 μL for standard panel) Buffer composition and pH Species/strain identification Storage conditions and shipping temperature	Prior bioactivity data or screening results Specific functional hypothesis (anti-inflammatory, barrier repair, immunomodulatory) Target cell type or tissue of interest Reference batch for comparative potency Mechanistic pathway of interest Regulatory documentation requirements	Samples with visible aggregation or precipitation Samples in fixatives or organic solvents Samples without proper cold-chain documentation Intact bacterial/fungal cell cultures Contaminated or mixed samples Samples shipped at room temperature

Recommended Sample Quantity by Assay:

Assay	Minimum Volume	Recommended Volume
Macrophage polarization	100 μL	200 μL
Anti-inflammatory cytokine profiling	50 μL	100 μL
Barrier repair (TEER/permeability)	150 μL	300 μL
Cellular uptake kinetics	100 μL	200 μL
Intracellular trafficking	150 μL	300 μL
Mechanism-of-action pathway panel	100 μL	200 μL
Standard functional package	300 μL	600 μL

Storage & Shipping: Ship purified vesicle suspensions on dry ice (–80°C) or wet ice (4°C) with cold-chain documentation. Avoid repeated freeze-thaw cycles. Recommended buffer: sterile PBS. For anti-inflammatory assays, avoid buffers containing endotoxin. Provide NTA-derived particle concentration if available.

Inquiry

Our Advantages

Microbial EV-Specific Cell Models: Our macrophage polarization, anti-inflammatory, and barrier repair assays are calibrated against microbial vesicle matrices. We perform LAL endotoxin testing on every preparation to exclude LPS-driven artifacts that confound functional interpretation for Gram-negative OMVs.
Integrated Functional Profiling: We assess mEV activity across multiple orthogonal endpoints (immunomodulation, cytokine suppression, barrier repair, cellular uptake) under standardized conditions, providing a comprehensive functional profile that single-endpoint assays cannot deliver.
Mechanistic Insight Integration: Our NF-κB reporter assays, TLR pathway panels, MAPK profiling, and NLRP3 inflammasome studies connect functional readouts to molecular mechanisms, enabling rational product engineering and supporting intellectual property claims.
Barrier Repair Specialization: We offer TEER-based barrier integrity assessment, tight junction protein quantification, and immune-epithelial co-culture models specifically designed for gut-targeted probiotic vesicle and therapeutic mEV validation.
Regulatory-Ready Documentation: Assay protocols, dose-response curves, and mechanism-of-action data are prepared in formats suitable for CMC packages, potency specifications, and regulatory submissions.

Applications

Probiotic mEV anti-inflammatory validation application showing left-to-right workflow from probiotic vesicle treatment through macrophage cytokine suppression to reduced intestinal inflammation.

Probiotic mEV Anti-Inflammatory Product Validation

Macrophage polarization and cytokine profiling validate anti-inflammatory potency of probiotic-derived vesicles.

OMV vaccine adjuvant immunomodulatory screening application showing central OMV particle with surrounding dendritic cell activation, macrophage polarization, and cytokine induction modules.

OMV Vaccine Adjuvant Immunomodulatory Screening

In vitro immunomodulatory assays validate OMV adjuvant potency and support vaccine development.

Therapeutic mEV barrier repair development application showing top-to-bottom cascade from inflammatory barrier disruption through vesicle-mediated tight junction restoration to healed intestinal epithelium.

Therapeutic mEV Barrier Repair Development

TEER and tight junction assays validate gut barrier repair for inflammatory bowel disease therapeutic candidates.

Cosmetic mEV skin barrier function testing application showing scale transition from skin surface to keratinocyte tight junctions with microbial vesicle-mediated barrier reinforcement and hydration indicators.

Cosmetic mEV Skin Barrier Function Testing

In vitro barrier models validate cosmetic vesicle actives for skin barrier strengthening claims.

FAQs

Q: How do you distinguish true anti-inflammatory activity from endotoxin artifacts?

A: We perform LAL endotoxin testing on every vesicle preparation. For Gram-negative OMVs, we include heat-inactivated vesicle controls (which destroy protein bioactivity while preserving LPS structural components for comparison) and polymyxin B controls to separate protein-mediated bioactivity from endotoxin-driven effects. If endotoxin levels exceed assay-appropriate thresholds for the specific cell model and vesicle type, we flag the result and recommend additional controls or purification optimization.

Q: Can you test mEVs on primary human cells?

A: Yes. We offer functional testing on primary human PBMCs, primary human monocyte-derived macrophages, and primary human intestinal epithelial cells or intestinal organoids (where available). For PBMC and macrophage assays, we require donor material with appropriate consent documentation. Cell isolation and characterization are included in the service fee.

Q: What is the difference between M1 and M2 macrophage polarization?

A: M1 macrophages are pro-inflammatory, characterized by high expression of CD80, CD86, HLA-DR, and secretion of TNF-α, IL-6, and IL-12. M2 macrophages are anti-inflammatory and tissue-repairing, characterized by CD206, CD163, CD209 expression and secretion of IL-10 and TGF-β. Our assays quantify both phenotypes to determine whether mEVs promote anti-inflammatory M2 polarization or suppress pro-inflammatory M1 activation.

Q: How do you measure intestinal barrier repair?

A: We use Caco-2 or HT-29 cell monolayers on Transwell inserts. Barrier integrity is measured by TEER (transepithelial electrical resistance) and FITC-dextran paracellular permeability. Tight junction restoration is assessed by ZO-1, occludin, and claudin immunofluorescence and Western blot. For inflammation-induced disruption, monolayers are challenged with TNF-α/IFN-γ or LPS before mEV treatment.

Q: Can you track mEV cargo delivery into cells?

A: Yes. We offer fluorescent cargo tracking using labeled siRNA, proteins, or small molecules loaded into mEVs. Intracellular release is monitored by live-cell confocal microscopy, and co-localization with endosomal/lysosomal markers (EEA1, LAMP1) determines trafficking routes and cytosolic release efficiency.

Q: What pathway analysis options do you offer?

A: Our standard mechanism-of-action panel covers NF-κB, MAPK (ERK, p38, JNK), PI3K-Akt, STAT, and NLRP3 inflammasome pathways. We use reporter gene assays, phosphorylation-specific Western blots, and targeted qPCR. Custom pathway panels can be designed based on client hypotheses or preliminary screening data.

Q: Can you compare functional potency across different mEV batches?

A: Yes. We offer comparative functional analysis that profiles multiple batches side-by-side under identical assay conditions. Statistical comparison includes ANOVA with post-hoc testing, equivalence margins (e.g., 80–125% relative potency), and control chart trending for ongoing batch monitoring.

Q: Is your functional assay service compatible with GxP requirements?

A: Our standard service is research-grade (R&D) with validated methods and full QC documentation. GxP-aligned potency assay validation (per ICH Q2(R1) and ICH Q6B guidelines), including accuracy, precision, specificity, linearity, and robustness, is available as a custom service. Contact us to discuss your regulatory pathway requirements.

Services

Inquiry